MARKET

CAI

CAI

Caris Life Sciences, Inc.
NASDAQ
27.46
-2.94
-9.66%
After Hours: 27.50 +0.05 +0.16% 18:00 10/06 EDT
OPEN
30.69
PREV CLOSE
30.39
HIGH
32.56
LOW
27.29
VOLUME
4.75M
TURNOVER
--
52 WEEK HIGH
33.66
52 WEEK LOW
14.19
MARKET CAP
7.76B
P/E (TTM)
74.85
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CAI last week (0928-1002)?
Weekly Report · 1d ago
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Seeking Alpha · 09/29 11:30
Weekly Report: what happened at CAI last week (0921-0925)?
Weekly Report · 09/28 09:45
GRAIL sets new 52-week high as FDA panel backs cancer test
Seeking Alpha · 09/24 15:56
Grail panel votes ‘closer than we expected,’ says BTIG
TipRanks · 09/24 13:36
This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
MarketWatch · 09/23 12:58
Caris Life Sciences: Adjusting My Position After A Recent Steep Incline (Downgrade)
Seeking Alpha · 09/22 06:21
Goldman Sachs Remains a Buy on Caris Life Sciences, Inc. (CAI)
TipRanks · 09/21 12:26
More
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Webull offers Caris Life Sciences, Inc. stock information, including NASDAQ: CAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CAI stock methods without spending real money on the virtual paper trading platform.